Panacea Biotec growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+14.4%−0.0%+21.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+82.0%−29.2%+79.5%
+37.9%−7.0%+58.6%
+17.9%−481.3%+95.6%
+35.8%−621.1%+96.6%
−2.1%+4.0%−2.4%
−0.2%−0.9%−0.2%
+160.9%−27,270.0%+100.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+21.6-0.0+14.4—
EBITDA Growth—+79.5-29.2+82.0—
EBIT Growth—+58.6-7.0+37.9—
Net Income Growth—+95.6-481.3+17.9—
EPS Growth—+96.6-621.1+35.8—
Total Assets Growth—-2.4+4.0-2.1—
Total Equity Growth—-0.2-0.9-0.2—
Cash from Operations Growth—+100.0-27,270.0+160.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.